Melphalan/total body irradiation-conditioned myeloablative allogeneic hematopoietic cell transplantation for patients with primary plasma cell leukemia

Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):e225-8. doi: 10.1016/j.clml.2014.07.012. Epub 2014 Aug 2.

Authors

Daniel J Landsburg¹, Dan T Vogl², John P Plastaras², Edward A Stadtmauer²

Affiliations

¹ Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA. Electronic address: daniel.landsburg@uphs.upenn.edu.
² Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.

PMID: 25172535
DOI: 10.1016/j.clml.2014.07.012

No abstract available

Keywords: Allogeneic stem cell transplantation; Melphalan; Plasma cell leukemia; Total body irradiation.

Publication types

Case Reports

MeSH terms

Adult
Female
Graft vs Host Disease / drug therapy
Graft vs Host Disease / etiology
Hematopoietic Stem Cell Transplantation* / adverse effects
Humans
Leukemia, Plasma Cell / diagnosis
Leukemia, Plasma Cell / therapy*
Male
Melphalan / therapeutic use*
Middle Aged
Myeloablative Agonists / therapeutic use*
Transplantation Conditioning*
Transplantation, Homologous
Treatment Outcome
Whole-Body Irradiation*

Substances

Myeloablative Agonists
Melphalan